Performance of clinical trials (phase II, III, IV) for the pharmaceutical industry for molecules already on the market and those in their pre-authorisation stages (phases II and III).
The main diseases susceptible to improvement are high blood pressure, dyslipidaemia, diabetes mellitus, ischaemic heart disease, diabetic nephropathy, aging, etc.